Figure 3b shows that heterogeneity remained high within the MI with diabetes and MI subgroups, but all subgroups consistently demonstrated a significant NT-proBNP-lowering effect in the dapagliflozin group. This evidence concerns the gene NPPB and diabetes mellitus.